Document Detail


Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer.
MedLine Citation:
PMID:  7685834     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have developed a new hypersensitive enzyme immunoassay for prostate specific antigen (PSA) based on the (MARKIT-M PA) assay but employing a two-hour incubation of the primary monoclonal antibody. The analytical sensitivity has been determined at 0.2 ng/ml, calculated as the mean+three standard deviations of the zero calibrator. Serum PSA was measured at least one month after radical prostatectomy (nine patients) or cystoprostatectomy (six patients). Based on the PSA levels of these patients, the recommended PSA cut-off level indicative of residual disease after radical prostatectomy was 0.4 ng/ml. Increasing (> 0.4 ng/ml) PSA levels preceded recurrence by eight months in a patient who developed bone metastasis after radical prostatectomy. In two patients treated with endocrine therapy, increasing PSA levels also preceded clinical evidence of progression by between eight and nine months. The study suggests that the newly developed sensitive PSA assay allows for the identification of patients with disease progression and the early commencement of adjuvant treatment.
Authors:
Y Arai; H Onishi; K Oishi; H Takeuchi; O Yoshida
Related Documents :
2231934 - Clinical and pathological findings in prostates following intravesical bacillus calmett...
8857614 - Combinations of maximum urinary flow rate and american urological association symptom i...
9329584 - Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphat...
7672704 - The effect of renal function on serum levels of ca 125.
8149634 - Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glyco...
10484004 - Ischemic colitis associated with pseudoephedrine: four cases.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Japanese journal of clinical oncology     Volume:  23     ISSN:  0368-2811     ISO Abbreviation:  Jpn. J. Clin. Oncol.     Publication Date:  1993 Apr 
Date Detail:
Created Date:  1993-07-22     Completed Date:  1993-07-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0313225     Medline TA:  Jpn J Clin Oncol     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  110-5     Citation Subset:  IM    
Affiliation:
Department of Urology, Faculty of Medicine, Kyoto University.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Immunoenzyme Techniques
Male
Prostate-Specific Antigen / blood*
Prostatectomy
Prostatic Hyperplasia / immunology
Prostatic Neoplasms / immunology*,  therapy
Regression Analysis
Reproducibility of Results
Sensitivity and Specificity
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Low dose lidocaine combined with magnesium sulfate in warning ventricular arrhythmias.
Next Document:  Cisplatin, vindesine, pepleomycin and combined radiation therapy for inoperable esophageal carcinoma...